Clinical Trials Sponsored by Renew Research, LLC

Total 1872 results

Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, China, Germany, United States, Brazil, Italy, Spain, France, Canada, Japan, Poland, Turkey, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab

Multiple Myeloma

Korea, Republic of, United States, Russian Federation, Spain, France, China, Germany, Belgium, Denmark, Greece, Ukraine, Poland
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA)

Myositis

United States, Korea, Republic of, Italy, United Kingdom, Hungary, Spain, Japan, Czechia, France, Mexico, Germany, Canada, Poland
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

Relapsed/ Refractory Multiple Myeloma

United States, Germany, Spain, France
Janssen Research & Development, LLC

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

United States, China, Taiwan, Korea, Republic of, Japan, France, Portugal, Spain, Czechia, Greece, Poland, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Japan, Netherlands, Poland
Urological Research Network, LLC

Recruiting

Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach (RCAPN)

Kidney Neoplasms

United States
Janssen Research & Development, LLC

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Multiple Myeloma

United States, Belgium, China, Israel, Netherlands, Spain, Japan
Janssen Research & Development, LLC

Recruiting

A Long-term Extension Study of Ustekinumab in Pediatric Participants (UNITED)

Crohn Disease | Arthritis, Psoriatic | Colitis, Ulcerative

Belgium, United Kingdom, France, United States, Hungary, Japan, Germany, Poland, Argentina
Janssen Research & Development, LLC

Recruiting

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)

Arthritis, Juvenile

United States, France, Spain, United Kingdom, Turkey, Argentina, Germany, Italy, Poland, Denmark
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Korea, Republic of, Japan, Taiwan, Denmark, Germany, Czechia, China, Spain, Belgium, Canada, Mexico, Poland, Italy, France, Australia, Sweden
Janssen Research & Development, LLC

Recruiting

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

Arthritis, Psoriatic

Turkey, United States, Australia, Russian Federation, Ukraine, Puerto Rico, Spain, Israel, Hungary, Poland, Bulgaria, Malaysia, Argentina, Czechia
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Canada, Spain, Sweden, Germany, Australia, Netherlands, France, Argentina, Brazil, Denmark, Greece, Poland, Ireland, Hungary, Portugal, F... and more
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Prostatic Neoplasms

United States, France, Spain, Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-75276617 in Participants With Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemias

United States, United Kingdom, France, Spain, Australia
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Adenocarcinoma | Prostatic Neoplasms

United States
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

Urinary Bladder Neoplasms

United States, Belgium, Korea, Republic of, Germany, Italy, France, Spain, Canada, United Kingdom, Greece, Japan, Australia, Netherlands, Portugal, Russian Federation, Ukraine
Janssen Research & Development, LLC

Recruiting

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (RedirecTT-1)

Multiple Myeloma

United States, Korea, Republic of, Canada, Israel, Australia, Spain, Japan
Janssen Research & Development, LLC

Recruiting

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

United States, Netherlands, Spain, France, Sweden
Urological Research Network, LLC

Recruiting

MRI/Ultrasound Fusion Guided Prostate Cryotherapy (FIPC)

Cancer of the Prostate | Neoplasms Prostate

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection (PENGUIN)

Hepatitis B, Chronic

Taiwan, Poland, Japan, New Zealand
Janssen Research & Development, LLC

Active, not recruiting

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

United States, France, United Kingdom, Belgium, Germany, Israel, Australia, Sweden, Canada, Netherlands, Austria, Ireland, Denmark
Janssen Research & Development, LLC

Completed

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Healthy

United States, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Healthy Non-dependent, Recreational Sedative Users | Abuse Potential

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Urothelial Carcinoma

France, United States, Korea, Republic of, Belgium, Taiwan, Turkey, Russian Federation, Spain, Italy, United Kingdom, Brazil, Belarus, Poland
Janssen Research & Development, LLC

Active, not recruiting

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Urothelial Cancer

United States, France, Germany, United Kingdom, Belgium, Taiwan, Spain, Israel, India, Romania, Korea, Republic of, Russian Federation, Turkey, Austria, Moldova, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease (Autonomy)

Cognitive Dysfunction | Dementia | Alzheimer Disease

United States, Belgium, France, Japan, United Kingdom, Spain, Canada, Australia, Sweden, Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Japan, Taiwan, Spain, United States, Argentina, Ukraine, Germany, Poland, Bulgaria, Colombia, South Africa, Hungary
Janssen Research & Development, LLC

Active, not recruiting

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) (UNIFI Jr)

Colitis, Ulcerative

United States, Israel, Belgium, Hungary, Japan, Germany, Poland, United Kingdom, Russian Federation
Janssen Research & Development, LLC

Active, not recruiting

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

Crohn's Disease

United States, Israel, Japan, Belgium, Lebanon, Taiwan, Netherlands, Russian Federation, Korea, Republic of, Jordan, France, Portugal, Greece, Canada, Germany, Malaysia, Belarus, Latvia, Poland, Australia, Italy, Croatia, Turkey, China, United Kingdom and more
Janssen Research & Development, LLC

Active, not recruiting

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PURSUIT 2)

Colitis, Ulcerative

United States, Korea, Republic of, Taiwan, Israel, Spain, France, Brazil, Belgium, Poland, Italy, Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Prostatic Neoplasms

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, Israel, Japan, Germany, Spain, Australia, China, France, United Kingdom, Greece, Italy
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

Carcinoma, Non-Small-Cell Lung

Canada, Germany, Italy, China, Belgium, United States, Taiwan, Israel, United Kingdom, Sweden, Japan, Poland, Korea, Republic of, Malaysia, Netherlands, Spain, Turkey, France, India, Mexico, Argentina, Brazil, Portugal, Russian Federation and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Germany, Japan, China, Israel, Belgium, Italy, France, Taiwan, Thailand, Korea, Republic of, Malaysia, Spain, Hungary, Turkey, Portugal, India, Poland, Australia, Russian Federation, Mexico, Brazil, Puerto Rico, U... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Israel, Korea, Republic of, Netherlands, Belgium, Australia, Poland, Spain, France, Georgia, Moldova, Republic of, Ukraine
Janssen Research & Development, LLC

Active, not recruiting

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

Prostatic Neoplasms

United States, Italy, Czechia, Israel, Japan, Taiwan, Korea, Republic of, United Kingdom, France, Spain, Germany, Australia, Canada, Brazil, Russian Federation, Argentina, Netherlands, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

Urothelial Cancer

Korea, Republic of, United States, Italy, Spain, Japan, United Kingdom, Belgium, Israel, China, Austria, France, Canada, Taiwan, Turkey, Germany, Russian Federation, Bulgaria, Poland, Greece, Brazil, Netherlands, Australia, Argentina, Mexic... and more
Janssen Research & Development, LLC

Active, not recruiting

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (VISIBLE)

Plaque Psoriasis | Scalp Psoriasis

United States, Canada
Janssen Research & Development, LLC
Janssen Research & Development, LLC

Active, not recruiting

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

X-Linked Retinitis Pigmentosa

United States, Canada, Israel, United Kingdom, Denmark, France, Belgium, Italy, Netherlands, Switzerland, Spain
Clinical Research Associates, LLC

Active, not recruiting

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

16P11.2 Deletion Syndrome

United States
Janssen Research & Development, LLC

Terminated

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Depressive Disorder, Major

United States, Spain, Italy, United Kingdom
Janssen Research & Development, LLC

Suspended

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

Healthy

United States, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants (OCTOPUS-1)

Hepatitis B, Chronic

France, Canada, Czechia, Italy, Taiwan, Turkey, Spain, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe Illness (BREEZE)

Acute Respiratory Viral Infection

United States, Canada
Janssen Research & Development, LLC

Terminated

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Korea, Republic of, Malaysia, Poland, Finland, Chile, Argentina, Slovakia, Ukraine, Denmark
Janssen Research & Development, LLC

Completed

A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn

Erythroblastosis, Fetal | Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN)

United States, Canada, Netherlands, Belgium, Australia, Germany, Spain, Sweden, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Multiple Myeloma

United States, France, Spain
Janssen Research & Development, LLC

Completed

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, Poland, Ukraine, Germany, Spain, Turkey, Korea, Republic of, Brazil, Russian Federation, Netherlands, Hungary, Sweden, Czechia, Mexico
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Czechia, Israel, Italy, Korea, Republic of, Brazil, United Kingdom, Japan, Taiwan, Australia, Poland, Spain, France, Russian Federation, Sweden, Ukraine, Greece

Clinical Trials Sponsored by Renew Research, LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations